SLC5A2 and heart failure: Two ongoing outcome trials are testing the effects of dapagliflozin vs. placebo(DAPA-MI) on the composite endpoint cardiovascular death and hospitalization forheart failure and of empagliflozin vs. placebo (EMPACT-MI) on the compositeendpoint time to first heart failure hospitalisation or all-cause mortality.Longitudinal data on functional and structural parameters after SGLT2 inhibitoruse is scarce and no data available in post MI patients.